In that study, MHCII expressing lymphoma cells were associated with a TME rich in a CD4+ T-cell population with a high cytotoxicity expression profile signature (CD4CTL), while the reverse was observed for cells expressing low levels of MHCII (Han et al., 2022b). The gene discussed is CD4; the disease is lymphoma.